Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market

Chapter 1 Introduction

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 Assumptions

1.5 List of Abbreviations

Chapter 2 Executive Summary

2.1 Market Snapshot: Global HPV Therapeutics Market

2.2 Market Snapshot: Global CMV Therapeutics Market

2.3 Global HPV and CMV Therapeutics Market  Revenue, 2012 – 2020 (USD Million)

Chapter 3 Global HPV and CMV Therapeutics Market Overview

3.1 Market Definition and Overview

3.2 Market Dynamics

      3.2.1 Human Papillomavirus (HPV) Therapeutics Market

              3.2.1.1 Drivers

                         3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped economies is aiding the market growth

                         3.2.1.1.2 Global Age-specific incidence of cervical cancer

                         3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and creating opportunity for therapeutics market

              3.2.1.2 Restraints

                         3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts treatment

                         3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates

                                      3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions (estimations for 2012)

              3.2.1.3 Opportunities

                         3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime against HPV infections

                         3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of opportunities for effective and safe vaccines and therapeutics

      3.2.2 Cytomegalovirus Therapeutics Market

              3.2.2.1 Drivers

                         3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market

                         3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middle-income countries in South Latin America and Asia Pacific

              3.2.2.2 Restraints

                         3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART) and decreasing transplant procedures

              3.2.2.3 Opportunities

                         3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV vaccine

3.3 Value Chain Analysis

3.4 HPV Vaccines : Current Global Scenario

3.5 HPV Drug Treatment Regime Analysis: Length of HPV Drug treatment (No. of days)

3.6 HPV Surgery Treatment: Type of Surgery and Average Cost (USD)

3.7 Pricing Analysis

      3.7.1 Pricing Analysis: HPV Therapeutics Market

      3.7.2 Pricing Analysis: CMV Therapeutics Market

      3.7.3 HPV Treatment Cost Analysis

      3.7.4 CMV Treatment Cost Analysis

3.8 Porter’s Five Forces Analysis: Global HPV & CMV Therapeutics Market

      3.8.1 Bargaining Power of Suppliers

      3.8.2 Bargaining Power of Buyers

      3.8.3 Threat of Substitutes

      3.8.4 Threat of New Entrants

      3.8.5 Competitive Rivalry

3.9 Market Attractiveness Analysis, by Geography, 2013

      3.9.1 HPV Therapeutics Market Attractiveness Analysis, Geography, 2013

      3.9.2 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013

3.10 Market Share Analysis, by Key Players, 2013 (Value %)

      3.10.1 HPV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)

      3.10.2 CMV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)

Chapter 4 Global  HPV Therapeutics Market

4.1 Overview

4.2 HPV Therapeutics Market, by Drug Class

      4.2.1 Overview

              4.2.1.1 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)

      4.2.2 Immunomodulators

              4.2.2.1 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)

      4.2.3 Keratolytic Agents

              4.2.3.1 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)

      4.2.4 Anti-neoplastic Agents

              4.2.4.1 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)

      4.2.5 Sinecatechins

              4.2.5.1 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)

4.3 HPV Therapeutics Market, by Application

      4.3.1 Overview

              4.3.1.1 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

      4.3.2 Genital Warts

              4.3.2.1 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      4.3.3 Genital Cancer

              4.3.3.1 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.4 Epidermodysplasia Verruciformis

              4.3.4.1 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.5 Oral Papillomas

              4.3.5.1 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      4.3.6 Others (Oropharyngeal cancer, laryngeal papillomatosis and others)

              4.3.6.1 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

4.4 HPV Therapeutics Market, Pipeline Analysis

      4.4.1 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

      4.4.2 HPV Therapeutics: Late Stage (Phase III) Drug Candidates

Chapter 5 Global Cytomegalovirus Therapeutics Market

5.1 Introduction

      5.1.1 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

5.2 CMV Therapeutics Market, by Major Antiviral Drugs

      5.2.1 Overview

              5.2.1.1 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)

      5.2.2 Ganciclovir/Valganciclovir

              5.2.2.1 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)

      5.2.3 Foscarnet

              5.2.3.1 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)

      5.2.4 Cidofovir

              5.2.4.1 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)

5.3 CMV Therapeutics Market, by Applications

      5.3.1 Overview

              5.3.1.1 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

      5.3.2 CMV Retinitis

              5.3.2.1 Global CMV Retinitis Therapeutics Market Revenue,2012 - 2020 (USD Million)

      5.3.3 Pneumonia

              5.3.3.1 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.4 Gastrointestinal ulcers

              5.3.4.1 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.5 Encephalitis

              5.3.5.1 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

      5.3.6 Others (Mouth ulcers, pharyngitis)

              5.3.6.1 Global Other (Mouth ulcers, Pharyngitis)CMV Therapeutics Market Revenue,2012 - 2020 (USD Million)

5.4 CMV Therapeutics Market, Pipeline Analysis

      5.4.1 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

      5.4.2 CMV Therapeutics: Late Stage (Phase III) Drug Candidates

              5.4.2.1 Introduction

                         5.4.2.1.1 MK8228/ letermovir/AIC246

                                      5.4.2.1.1.1 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)

                         5.4.2.1.2 Brincidofovir/CMX001

                                      5.4.2.1.2.1 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)

Chapter 6 Global HPV and CMV Therapeutics Market, by Geography

6.1 Overview

      6.1.1 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

              6.1.1.1 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

6.2 North America

      6.2.1 North America HPV Therapeutics Market

              6.2.1.1 North America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.2.2 North America CMV Therapeutics Market

              6.2.2.1 North America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.3 Europe

      6.3.1 Europe HPV Therapeutics Market

              6.3.1.1 Europe HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.3.2 Europe CMV Therapeutics Market

              6.3.2.1 Europe CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.4 Asia Pacific

      6.4.1 Asia Pacific HPV Therapeutics Market

              6.4.1.1 Asia Pacific HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.4.2 Asia Pacific CMV Therapeutics Market

              6.4.2.1 Asia Pacific CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.5 South America

      6.5.1 South America HPV Therapeutics Market

              6.5.1.1 South America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.5.2 South America CMV Therapeutics Market

              6.5.2.1 South America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

6.6 Rest of the World

      6.6.1 Rest of the World HPV Therapeutics Market

              6.6.1.1 Rest of the World HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

      6.6.2 Rest of the World CMV Therapeutics Market

              6.6.2.1 Rest of the World CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

Chapter 7 Recommendations

      7.1.1 Market avails wide scope for new molecules as most of the first line drugs have been off patented

      7.1.2 Building stronger market hold in Africa

Chapter 8 Company Profiles

8.1 AbbVie, Inc.

      8.1.1 Company Overview

      8.1.2 Financial Overview

      8.1.3 Product Portfolio

      8.1.4 Business Strategies

              8.1.4.1 Strategic Collaborations and Agreements

      8.1.5 Mergers and Acquisitions

      8.1.6 Recent Developments

8.2 Actavis plc

      8.2.1 Company Overview

      8.2.2 Financial Overview

      8.2.3 Product Portfolio

      8.2.4 Business Strategies

              8.2.4.1 Mergers and acquisitions

              8.2.4.2 Extensive R&D practices

              8.2.4.3 Strategic collaborations

      8.2.5 Recent Developments

8.3 Clinigen Group plc

      8.3.1 Company Overview

      8.3.2 Financial Overview

      8.3.3 Product Portfolio

      8.3.4 Business Strategies

              8.3.4.1 Mergers and Acquisitions

      8.3.5 Recent Developments

8.4 Merck & Co., Inc.

      8.4.1 Company Overview

      8.4.2 Financial Overview

      8.4.3 Product Portfolio

      8.4.4 Business Strategies

              8.4.4.1 Mergers and acquisitions

              8.4.4.2 Strategic collaborations

              8.4.4.3 Expansion in emerging markets

      8.4.5 Recent Developments

8.5 Perrigo Company plc

      8.5.1 Company Overview

      8.5.2 Financial Overview

      8.5.3 Product Portfolio

      8.5.4 Business Strategies

      8.5.5 Mergers and Acquisitions

      8.5.6 Recent Developments

8.6 Roche Holdings AG

      8.6.1 Company Overview

      8.6.2 Financial Overview

      8.6.3 Product Portfolio

      8.6.4 Business Strategies

              8.6.4.1 Consistent product launches

              8.6.4.2 Mergers and Acquisitions

      8.6.5 Recent Developments

8.7 Valeant Pharmaceuticals International, Inc.

      8.7.1 Company Overview

      8.7.2 Financial Overview

      8.7.3 Product Portfolio

      8.7.4 Business Strategies

              8.7.4.1 Mergers and acquisitions

      8.7.5 Recent Developments

List of Tables

TABLE 1 Market Snapshot: Global HPV Therapeutics Market

TABLE 2 Market Snapshot: Global CMV Therapeutics Market

TABLE 3 HPV Vaccines Sales Track

TABLE 4 Pricing Analysis: HPV Therapeutics Market

TABLE 5 Pricing Analysis: CMV Therapeutics Market

TABLE 6 HPV Strains and Diseases

TABLE 7 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)

TABLE 8 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

TABLE 9 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

TABLE 10 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

TABLE 11 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)

TABLE 12 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)

TABLE 13 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates

TABLE 14 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

TABLE 15 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)

List of Figures

FIG. 1 HPV Therapeutics: Market Segmentation

FIG. 2 CMV Therapeutics: Market Segmentation

FIG. 3 Global HPV and CMV Therapeutics Market  Revenue, 2012 – 2020 (USD Million)

FIG. 4 Global Age-specific incidence of cervical cancer

FIG. 5 Annual number of new cases (in thousands) of cervical cancer by age group in developed and developing regions and five continents (estimations for 2012)

FIG. 6 Heat Map Analysis: Immunization Array of Currently Marketed Vaccines by Major Countries

FIG. 7 Global Human Immunodeficiency Virus (HIV) Prevalence, 1990 - 2008

FIG. 8 U.S. Transplant Procedures,  2000 - 2013

FIG. 9 Global HPV and CMV Therapeutics Market, Value Chain Analysis

FIG. 10 Porter’s Five Forces Analysis for the Global HPV & CMV Therapeutics Market

FIG. 11 HPV Therapeutics Market Attractiveness Analysis: by Geography, 2013

FIG. 12 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013

FIG. 13 HPV Therapeutics Market Share Analysis: by Key Players, 2013 (Value %)

FIG. 14 CMV Therapeutics Market Attractiveness Analysis: by Key Players, 2013 (Value %)

FIG. 15 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)

FIG. 16 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)

FIG. 17 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)

FIG. 18 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)

FIG. 19 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)

FIG. 20 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 21 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 22 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 23 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 24 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)

FIG. 25 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)

FIG. 26 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)

FIG. 27 Global CMV Retinitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 28 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 29 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 30 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 31 Global Other (Mouth ulcers, Pharyngitis) CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 32 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)

FIG. 33 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)

FIG. 34 North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 35 North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 36 Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 37 Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 38 Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 39 Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 40 South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 41 South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 42 Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 43 Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)

FIG. 44 Tuberculosis Cases in Africa, 1996 – 2010 (‘000)

FIG. 45 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 46 Actavis Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 47 Clinigen Group plc: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 48 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 49 Perrigo Company plc: Annual Revenue: 2011 – 2013 (USD Million)

FIG. 50 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)

FIG. 51 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)